GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Beta

BCAB (BioAtla) Beta : 0.90 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioAtla Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-13), BioAtla's Beta is 0.90.


BioAtla Beta Historical Data

The historical data trend for BioAtla's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Beta Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - - - 0.85

BioAtla Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.85 1.12 1.11 1.00

Competitive Comparison of BioAtla's Beta

For the Biotechnology subindustry, BioAtla's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAtla's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's Beta distribution charts can be found below:

* The bar in red indicates where BioAtla's Beta falls into.



BioAtla Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


BioAtla  (NAS:BCAB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioAtla Beta Related Terms

Thank you for viewing the detailed overview of BioAtla's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAtla Business Description

Traded in Other Exchanges
N/A
Address
11085 Torreyana Road, San Diego, CA, USA, 92121
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Executives
Sylvia Mcbrinn director
Short Jay M Phd director, 10 percent owner, officer: Chief Executive Officer C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez officer: See Remarks 121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith director, officer: President C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers officer: Chief Medical Officer 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron officer: Chief Financial Officer 901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy director, 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc 10 percent owner 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc 10 percent owner 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran director 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short 10 percent owner, officer: See Remarks 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142